Labcorp (LH) CEO Schechter sells shares and exercises RSUs in planned trades

Rhea-AI Filing Summary

Labcorp Holdings Inc. President and CEO Adam H. Schechter reported several equity transactions dated February 11, 2026. He sold 5,273 shares of common stock in an open-market transaction at $284.38 per share under a Rule 10b5-1 trading plan.

On the same day, he acquired 3,656 shares of common stock through the exercise and conversion of Restricted Stock Units, and 1,521 shares were withheld to cover tax obligations. Following these transactions, he directly held 89,478 common shares and 22,214 Restricted Stock Units, each RSU representing the right to receive one share of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schechter Adam H

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		S(1)		5,273	D	$284.38	87,343	D
Common Stock	02/11/2026		M		3,656	A	(2)	90,999	D
Common Stock	02/11/2026		F(3)		1,521	D	$289.89	89,478	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	02/11/2026		M			3,656	(4)	(4)	Common Stock	3,656	$0	22,214(5)	D

Explanation of Responses:

1. Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

2. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

3. Stock withholding to satisfy tax withholding obligations.

4. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026.

5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Adam H. Schechter	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Labcorp (LH) CEO Adam Schechter report on February 11, 2026?

Adam Schechter reported multiple transactions on February 11, 2026. He sold 5,273 Labcorp common shares, exercised 3,656 Restricted Stock Units into common stock, and had 1,521 shares withheld to satisfy tax obligations related to those equity awards.

At what price did the Labcorp (LH) CEO sell common stock in this Form 4 filing?

The CEO sold 5,273 Labcorp common shares at $284.38 per share. This sale was executed pursuant to a pre-established Rule 10b5-1 trading plan, which is designed to systematically schedule trades independently of day-to-day market developments.

How many Labcorp (LH) shares and RSUs does the CEO hold after these transactions?

After these transactions, Adam Schechter directly held 89,478 Labcorp common shares and 22,214 Restricted Stock Units. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp common stock upon vesting, according to the filing details.

What is the nature of the Restricted Stock Units reported in this Labcorp (LH) Form 4?

The filing states each Restricted Stock Unit gives the right to receive one Labcorp common share. The RSUs that vested on February 11, 2026 are from a grant vesting in three equal annual installments beginning on that date, with remaining units still outstanding.

Was any portion of the Labcorp (LH) CEO’s equity used to cover taxes in this filing?

Yes. The Form 4 indicates 1,521 Labcorp common shares were disposed of through stock withholding to satisfy tax withholding obligations. This tax-related disposition is coded as transaction type F and is distinct from open-market sales activity.

Was the Labcorp (LH) CEO’s stock sale made under a Rule 10b5-1 trading plan?

The filing explains the sale was made pursuant to a Rule 10b5-1 trading plan. Such plans allow insiders to pre-schedule trades in advance, providing a structured framework intended to separate trading decisions from material nonpublic information.